Literature DB >> 19888315

Peripheral neuropathies: Biomarkers for axonal damage in immune-mediated neuropathy.

Bart C Jacobs, Hugh J Willison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19888315     DOI： 10.1038/nrneurol.2009.161

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Glial fibrillary acidic protein in Guillain-Barré syndrome: Methodological issues.

Authors:  A Petzold; L Rosengren; M M Verbeek; Francesca Notturno; Christina M Caporale; Angelo Delauretis; Antonino Uncini
Journal:  Muscle Nerve       Date:  2009-05       Impact factor: 3.217

Review 2.  Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.

Authors:  Jaap J Plomp; Hugh J Willison
Journal:  J Physiol       Date:  2009-06-29       Impact factor: 5.182

3.  Beta 4 integrin and other Schwann cell markers in axonal neuropathy.

Authors:  A Quattrini; S Previtali; M L Feltri; N Canal; R Nemni; L Wrabetz
Journal:  Glia       Date:  1996-08       Impact factor: 7.452

4.  CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome.

Authors:  A Petzold; J Brettschneider; K Jin; G Keir; N M F Murray; N P Hirsch; Y Itoyama; M M Reilly; A Takeda; H Tumani
Journal:  Muscle Nerve       Date:  2009-07       Impact factor: 3.217

5.  Glial fibrillary acidic protein as a marker of axonal damage in chronic neuropathies.

Authors:  Francesca Notturno; Margherita Capasso; Angelo DeLauretis; Marinella Carpo; Antonino Uncini
Journal:  Muscle Nerve       Date:  2009-07       Impact factor: 3.217

Review 6.  Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?

Authors:  Johannes Brettschneider; Axel Petzold; Sigurd Süssmuth; Hayrettin Tumani
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

Review 7.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

Authors:  Pieter A van Doorn; Liselotte Ruts; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2008-10       Impact factor: 44.182

8.  Glial fibrillary acidic protein: a marker of axonal Guillain-Barrè syndrome and outcome.

Authors:  Francesca Notturno; Christina M Caporale; Angelo De Lauretis; Antonino Uncini
Journal:  Muscle Nerve       Date:  2008-07       Impact factor: 3.217

9.  A clinical prognostic scoring system for Guillain-Barré syndrome.

Authors:  Rinske van Koningsveld; Ewout W Steyerberg; Richard A C Hughes; Anthony V Swan; Pieter A van Doorn; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2007-07       Impact factor: 44.182

10.  Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

Authors:  R D Hadden; D R Cornblath; R A Hughes; J Zielasek; H P Hartung; K V Toyka; A V Swan
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.